# Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

> **NCT06663306** · PHASE1 · RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 19 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)
- Leptomeningeal Metastasis

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06663306
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-09
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06663306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06663306, "Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06663306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*